vs
Side-by-side financial comparison of AdvanSix Inc. (ASIX) and Guardian Pharmacy Services, Inc. (GRDN). Click either name above to swap in a different company.
AdvanSix Inc. is the larger business by last-quarter revenue ($359.9M vs $338.6M, roughly 1.1× Guardian Pharmacy Services, Inc.). Guardian Pharmacy Services, Inc. runs the higher net margin — 3.5% vs -0.8%, a 4.3% gap on every dollar of revenue. On growth, AdvanSix Inc. posted the faster year-over-year revenue change (9.4% vs -14.9%).
AdvanSix Inc. is an American chemical company that produces nylon 6 and related chemicals such as caprolactam and ammonium sulfate fertilizers. It operated as Honeywell's Resins and Chemicals division until 2016, when it was spun off as a separate company. The unit accounted for 3 percent of Honeywell's sales at the time. For 2019, revenue is estimated at $1.4 billion. The company traces its lineage to the H. W. Jayne Company, established 1884 in Frankford, Pennsylvania.
CVS Pharmacy Inc. is an American retail corporation. A subsidiary of CVS Health, it is headquartered in Woonsocket, Rhode Island. Originally named the Consumer Value Stores, it was founded in Lowell, Massachusetts, in 1963.
ASIX vs GRDN — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $359.9M | $338.6M |
| Net Profit | $-2.8M | $11.8M |
| Gross Margin | 7.6% | 19.8% |
| Operating Margin | -0.7% | — |
| Net Margin | -0.8% | 3.5% |
| Revenue YoY | 9.4% | -14.9% |
| Net Profit YoY | -892.9% | -44.3% |
| EPS (diluted) | $-0.11 | $0.19 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $338.6M | ||
| Q4 25 | $359.9M | $397.6M | ||
| Q3 25 | $374.5M | $377.4M | ||
| Q2 25 | $410.0M | $344.3M | ||
| Q1 25 | $377.8M | $329.3M | ||
| Q4 24 | $329.1M | — | ||
| Q3 24 | $398.2M | $314.4M | ||
| Q2 24 | $453.5M | — |
| Q1 26 | — | $11.8M | ||
| Q4 25 | $-2.8M | $20.9M | ||
| Q3 25 | $-2.6M | $9.8M | ||
| Q2 25 | $31.4M | $9.0M | ||
| Q1 25 | $23.3M | $9.4M | ||
| Q4 24 | $352.0K | — | ||
| Q3 24 | $22.3M | $-122.0M | ||
| Q2 24 | $38.9M | — |
| Q1 26 | — | 19.8% | ||
| Q4 25 | 7.6% | 21.5% | ||
| Q3 25 | 6.8% | 19.8% | ||
| Q2 25 | 14.3% | 19.8% | ||
| Q1 25 | 14.2% | 19.5% | ||
| Q4 24 | 3.4% | — | ||
| Q3 24 | 14.4% | 19.4% | ||
| Q2 24 | 17.9% | — |
| Q1 26 | — | — | ||
| Q4 25 | -0.7% | 7.7% | ||
| Q3 25 | -0.9% | 4.3% | ||
| Q2 25 | 7.7% | 3.7% | ||
| Q1 25 | 7.7% | 3.9% | ||
| Q4 24 | -3.9% | — | ||
| Q3 24 | 7.5% | -33.3% | ||
| Q2 24 | 11.5% | — |
| Q1 26 | — | 3.5% | ||
| Q4 25 | -0.8% | 5.3% | ||
| Q3 25 | -0.7% | 2.6% | ||
| Q2 25 | 7.7% | 2.6% | ||
| Q1 25 | 6.2% | 2.9% | ||
| Q4 24 | 0.1% | — | ||
| Q3 24 | 5.6% | -38.8% | ||
| Q2 24 | 8.6% | — |
| Q1 26 | — | $0.19 | ||
| Q4 25 | $-0.11 | — | ||
| Q3 25 | $-0.10 | — | ||
| Q2 25 | $1.15 | — | ||
| Q1 25 | $0.86 | — | ||
| Q4 24 | $0.02 | — | ||
| Q3 24 | $0.82 | — | ||
| Q2 24 | $1.43 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $19.8M | $4.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $815.2M | $150.0M |
| Total Assets | $1.7B | $320.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $4.7M | ||
| Q4 25 | $19.8M | $65.6M | ||
| Q3 25 | $23.7M | $36.5M | ||
| Q2 25 | $18.4M | $18.8M | ||
| Q1 25 | $8.3M | $14.0M | ||
| Q4 24 | $19.6M | — | ||
| Q3 24 | $17.3M | $37.2M | ||
| Q2 24 | $12.1M | — |
| Q1 26 | — | — | ||
| Q4 25 | — | $0 | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $34.3M | ||
| Q2 24 | — | — |
| Q1 26 | — | $150.0M | ||
| Q4 25 | $815.2M | $217.9M | ||
| Q3 25 | $818.2M | $195.5M | ||
| Q2 25 | $823.7M | $179.7M | ||
| Q1 25 | $794.4M | $163.2M | ||
| Q4 24 | $774.6M | — | ||
| Q3 24 | $766.4M | $133.9M | ||
| Q2 24 | $746.6M | — |
| Q1 26 | — | $320.8M | ||
| Q4 25 | $1.7B | $412.7M | ||
| Q3 25 | $1.7B | $390.0M | ||
| Q2 25 | $1.6B | $356.3M | ||
| Q1 25 | $1.6B | $334.0M | ||
| Q4 24 | $1.6B | — | ||
| Q3 24 | $1.5B | $348.0M | ||
| Q2 24 | $1.5B | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.00× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.26× | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $63.7M | $58.0M |
| Free Cash FlowOCF − Capex | $36.1M | — |
| FCF MarginFCF / Revenue | 10.0% | — |
| Capex IntensityCapex / Revenue | 7.7% | — |
| Cash ConversionOCF / Net Profit | — | 4.89× |
| TTM Free Cash FlowTrailing 4 quarters | $6.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $58.0M | ||
| Q4 25 | $63.7M | $34.6M | ||
| Q3 25 | $26.6M | $28.2M | ||
| Q2 25 | $21.1M | $19.9M | ||
| Q1 25 | $11.4M | $17.6M | ||
| Q4 24 | $64.2M | — | ||
| Q3 24 | $57.3M | — | ||
| Q2 24 | $50.2M | — |
| Q1 26 | — | — | ||
| Q4 25 | $36.1M | — | ||
| Q3 25 | $66.0K | $24.2M | ||
| Q2 25 | $-7.2M | — | ||
| Q1 25 | $-22.6M | — | ||
| Q4 24 | $29.8M | — | ||
| Q3 24 | $26.8M | — | ||
| Q2 24 | $16.7M | — |
| Q1 26 | — | — | ||
| Q4 25 | 10.0% | — | ||
| Q3 25 | 0.0% | 6.4% | ||
| Q2 25 | -1.7% | — | ||
| Q1 25 | -6.0% | — | ||
| Q4 24 | 9.1% | — | ||
| Q3 24 | 6.7% | — | ||
| Q2 24 | 3.7% | — |
| Q1 26 | — | — | ||
| Q4 25 | 7.7% | — | ||
| Q3 25 | 7.1% | 1.1% | ||
| Q2 25 | 6.9% | — | ||
| Q1 25 | 9.0% | — | ||
| Q4 24 | 10.4% | — | ||
| Q3 24 | 7.7% | — | ||
| Q2 24 | 7.4% | — |
| Q1 26 | — | 4.89× | ||
| Q4 25 | — | 1.65× | ||
| Q3 25 | — | 2.87× | ||
| Q2 25 | 0.67× | 2.21× | ||
| Q1 25 | 0.49× | 1.86× | ||
| Q4 24 | 182.29× | — | ||
| Q3 24 | 2.57× | — | ||
| Q2 24 | 1.29× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ASIX
| Plant Nutrients | $140.0M | 39% |
| Chemical Intermediates | $92.8M | 26% |
| Caprolactam | $64.4M | 18% |
| Nylon Resins | $62.8M | 17% |
GRDN
Segment breakdown not available.
